Halozyme Therapeutics, Inc., founded in 1998 and re-incorporated from Nevada in Delaware in November 2007, is a biopharmaceutical company focused on developing and commercializing innovative therapies that improve patient care. The company's research centers on the extracellular matrix, and the structural network surrounding the cell plays a crucial role in tissue integrity, cell signaling, migration and survival. With extensive expertise accumulated through years of research, Halozyme leverages its deep scientific understanding of ECM to develop new therapeutic methods and drug delivery technologies for this complex and biologically rich environment, aiming to advance the next generation of therapeutic solutions. 

Expected P&L on Expiry

Key Stats

Pricing Model

About HALO20260918C110